The care needs of older patients with bipolar disorder

Abstract

Objectives: With aging, bipolar disorder evolves into a more complex illness, with increasing cognitive impairment, somatic comorbidity, and polypharmacy. To tailor treatment of these patients, it is important to study their needs, as having more unmet needs is a strong predictor of a lower quality of life.

Method: Seventy-eight Dutch patients with bipolar I or II disorder aged 60 years and older in contact with mental health services were interviewed using the Camberwell Assessment of Need in the Elderly (CANE) to assess met and unmet needs, both from a patient and a staff perspective.

Results: Patients (mean age 68 years, range 61–98) reported a mean of 4.3 needs compared to 4.4 reported by staff, of which 0.8 were unmet according to patients and 0.5 according to staff. Patients frequently rated company and daytime activities as unmet needs. More current mood symptoms were associated with a higher total number of needs. Less social participation was associated with a higher total number of needs and more unmet needs.

Conclusion: Older bipolar patients report fewer needs and unmet needs compared to older patients with depression, schizophrenia, and dementia. A plausible explanation is that older bipolar patients had higher Global Assessment of Functioning scores, were better socially integrated, and had fewer actual mood symptoms, all of which correlated with the number of needs in this study. The results emphasize the necessity to assess the needs of bipolar patients with special attention to social functioning, as it is suggested that staff fail to recognize or anticipate these needs.

Keywords:

• bipolar
• older
• CANE
• need assessment

Acknowledgement

The authors want to thank Maïlis Michaud, Sophie Punten, and Ruud Toonen for their help with the English language.

Disclosure statement

AB has received unrestricted grants for research from Eli Lilly, Astra Zeneca, Jansen and Shire, he has received honoraries as a speaker from Eli Lilly and Lundbeck; RK has received unrestricted research grants from AstraZeneca, honoraria as a speaker from AstraZeneca, Lundbeck, BristolMyersSquibb, and royalties from Wolters Kluwer Health PDM: has received an unrestricted research grant from AstraZeneca; AD, GD, LL, MLS: none.